 WALTHAM, Mass. , Oct. 27, 2022 PRNewswire -- Syndax Pharmaceuticals, Inc. Nasdaq: SNDX, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on Thursday, November 3, after the close of the U.S. financial markets. 